Neurogene, Inc. is a clinical-stage biotechnology company, which engages in the development of product portfolio of genetic medicines for rare neurological diseases. The company was founded in January 2018 and is headquartered in New York, NY.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
91
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Neoleukin Therapeutics Inc market cap is $385.08M.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Neoleukin Therapeutics Inc 52 week high is $53.00 as of November 22, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Neoleukin Therapeutics Inc 52 week low is $12.20 as of November 22, 2026.
Neoleukin Therapeutics Inc stock price today is $33.44.
Neoleukin Therapeutics Inc stock price yesterday was $29.96.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Neoleukin Therapeutics Inc's P/E ratio is -15.69.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Neoleukin Therapeutics Inc P/B ratio is 2.0653.
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company's operations. Neoleukin Therapeutics Inc's EBITDA is -1.24.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Neoleukin Therapeutics Inc 50-day moving average is $37.41.